Document:

EX-10.1

 Exhibit 10.1 

SUPPORT AGREEMENT 

This SUPPORT AGREEMENT (this “Agreement”), dated as of January 5, 2017, is by and among OncoGenex Pharmaceuticals,
Inc., a Delaware corporation (the “Company”, or “Arrow”), and the equityholders of Achieve Life Science, Inc., a Delaware corporation (“Ash”), set forth on Schedule A hereto (each, an
“Equityholder” and collectively, the “Equityholders”). 
 WHEREAS, as of the date hereof, each
Equityholder is the holder of the number of shares of common stock, par value $0.01 per share, of Ash (“Ash Common Stock”) set forth opposite such Equityholder’s name on Schedule A (all such shares of Ash Common Stock
set forth on Schedule A, the “Subject Shares”);
 WHEREAS, Arrow, Ash Acquisition Sub, Inc., Ash Acquisition
Sub 2, Inc. and the Company propose to enter into that certain Merger Agreement, dated as of the date hereof (the “Merger Agreement”). Capitalized terms used but not otherwise defined herein shall have the respective meanings
ascribed to such terms in the Merger Agreement; and 
 WHEREAS, as a condition to the Company’s willingness to enter into the
Merger Agreement and as an inducement and in consideration therefor, each Equityholder (in such Equityholder’s capacity as a holder of shares of Ash Common Stock) has agreed to, enter into this Agreement. 

NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth
below and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows: 

ARTICLE I 
 VOTING
AGREEMENT; GRANT OF PROXY 
 Each Equityholder hereby covenants and agrees that: 

1.1. Voting of Subject Shares. Subject to the remaining terms of this Section 1.1, at every meeting of the
holders of Ash Common Stock (the “Ash Stockholders”), however called, and at every adjournment or postponement thereof (or pursuant to a written consent if the Ash Stockholders act by written consent in lieu of a meeting), such
Equityholder shall, or shall cause the holder of record on any applicable record date to, be present (in person or by proxy) and to vote such Equityholder’s Subject Shares (a) to adopt the Merger Agreement and (b) to acknowledge that the
adoption given thereby is irrevocable.
 1.2. No Inconsistent Arrangements. Except as expressly permitted hereunder or
under the Merger Agreement, such Equityholder shall not, directly or indirectly, (a) create any Encumbrance other than restrictions imposed by applicable Law or pursuant to this Agreement on any shares of Ash Common Stock, (b) transfer, sell,
assign, encumber, pledge, grant, gift or otherwise dispose of (collectively, “Transfer”), or enter into any contract with respect to any Transfer of the shares of Ash Common Stock or any interest therein or publicly announce its
intention to Transfer any of its shares of Ash Common Stock, (c) grant or permit the grant of any proxy, power of attorney or other authorization in or with respect to the shares of Ash Common Stock, (d) deposit or permit the deposit of the Subject
Shares into a voting trust or enter into a voting agreement or arrangement with respect to the Subject Shares or (e) take any action that would make any representation or warranty of such Equityholder herein untrue or incorrect in any material
respect, or have the effect of preventing such Equityholder from performing such Equityholder’s obligations hereunder. Notwithstanding the foregoing, subject to any restrictions on transfer applicable to such shares of Ash Common Stock, (x)
such Equityholder may make Transfers of the shares of Ash Common Stock by will, operation of law, or for estate planning purposes, provided, the shares of Ash Common Stock shall continue to be bound by this Agreement and each transferee of
such shares of Ash Common Stock shall agree in writing to be bound by the terms and conditions 

 
of this Agreement and either such Equityholder or the transferee shall provide the Company with a copy of such agreement promptly upon consummation of any such Transfer and (y) such Equityholder
shall take all actions reasonably necessary to consummate the transactions contemplated by the Merger Agreement. 

1.3. Documentation and Information. Such Equityholder shall permit and hereby authorizes the Company and Ash to publish and
disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that the Company or Ash reasonably determines to be necessary in connection with the transactions contemplated by the Merger Agreement,
such Equityholder’s identity and ownership of the shares of Ash Common Stock and the nature of such Equityholder’s commitments and obligations under this Agreement. Each of Arrow and Ash is an intended third-party beneficiary of this
Section 1.3. 
 1.4. Irrevocable Proxy. Each Equityholder hereby revokes (or agrees to cause to be
revoked) any proxies that such Equityholder has heretofore granted with respect to the Subject Shares. Such Equityholder hereby irrevocably appoints the Company, and any individual designated in writing by it, as attorney-in-fact and proxy for and
on behalf of such Equityholder, for and in the name, place and stead of such Equityholder, to: (a) attend any and all meetings of the Ash Equityholders, (b) vote, express consent or dissent or issue instructions to the record holder to vote such
Equityholder’s Subject Shares in accordance with the provisions of Section 1.1 at any and all meetings of the Ash Equityholders or in connection with any action sought to be taken by written consent of the Ash Equityholders without a meeting
and (c) grant or withhold, or issue instructions to the record holder to grant or withhold, consistent with the provisions of Section 1.1, all written consents with respect to the Subject Shares at any and all meetings of the Equityholders or in
connection with any action sought to be taken by written consent without a meeting. The Company agrees not to exercise the proxy granted herein for any purpose other than the purposes expressly described in this Agreement. The foregoing proxy shall
be deemed to be a proxy coupled with an interest, is irrevocable (and as such shall survive and not be affected by the death, incapacity, mental illness or insanity of such Equityholder, as applicable) until the termination of the Merger Agreement
and shall not be terminated by operation of law or upon the occurrence of any other event other than the termination of this Agreement pursuant to Section 4.2. Such Equityholder authorizes such attorney and proxy to substitute any other Person
to act hereunder, to revoke any substitution and to file this proxy and any substitution or revocation with the Secretary of Ash. Such Equityholder hereby affirms that the proxy set forth in this Section 1.4 is given in connection with and granted
in consideration of and as an inducement to the Company to enter into the Merger Agreement and that such proxy is given to secure the obligations of such Equityholder under Section 1.1. The proxy set forth in this Section 1.4 is executed and
intended to be irrevocable, subject, however, to its automatic termination upon the termination of this Agreement pursuant to Section 4.2. 

1.5. No Solicitation of Merger. Without limiting and subject to the provisions of Section 4.14 hereof, such
Equityholder shall not, directly or indirectly, knowingly take any action that Ash is not permitted to take pursuant to Section 4 of the Merger Agreement. 

ARTICLE II 

REPRESENTATIONS AND WARRANTIES OF THE EQUITYHOLDERS 

Each Equityholder, severally but not jointly as to any other Equityholder, represents and warrants to the Company that: 

2.1. Authorization; Binding Agreement. Such Equityholder has full legal capacity, right and authority to
execute and deliver this Agreement and to perform such Equityholder’s obligations hereunder and to consummate the transactions contemplated hereby. Such Equityholder has full power and authority to execute, deliver and perform this Agreement.
This Agreement has been duly and validly executed and delivered by such Equityholder, and constitutes a valid and binding obligation of such Equityholder enforceable against such Equityholder in accordance with its terms, subject to the
Enforceability Exceptions. The execution and 

  
 2 

 
delivery by the Equityholder of this Agreement does not (a) conflict with or violate any law applicable to the Equityholder or by which any property or asset of the Equityholder is bound; or (b)
result in any breach or default under any Contract to which the Equityholder is a party or to which any of the Equityholder’s property or assets are subject, except, in each case, as would not reasonably be expected to adversely affect the
ability of the Equityholder to consummate the transactions contemplated by this Agreement, the Merger Agreement or the ancillary agreements to which the Equityholder is to be a party pursuant to the Merger Agreement. 

2.2. Ownership of Ash Common Stock; Total Shares. Such Equityholder is the sole record or beneficial owner (as defined in
Rule 13d-3 under the Exchange Act) of such Equityholder’s shares of Ash Common Stock listed on Schedule A opposite such Equityholder’s name and has good and marketable title to such shares of Ash Common Stock free and clear of any
Encumbrance (including, with respect to shares of Ash Common Stock, any restriction on the right to vote or otherwise transfer the shares of Ash Common Stock), except as (a) provided hereunder and (b) pursuant to any applicable restrictions on
transfer under the Securities Act. The shares of Ash Common Stock listed on Schedule A opposite such Equityholder’s name constitute all of the shares of Ash Common Stock owned by such Equityholder as of the date hereof. Except pursuant
to this Agreement, no Person has any contractual or other right or obligation to purchase or otherwise acquire any of such Equityholder’s shares of Ash Common Stock.

2.3. Voting Power. Except as set forth on Schedule A, such Equityholder has full voting power, with
respect to such Equityholder’s Subject Shares, and full power of disposition, full power to issue instructions with respect to the matters set forth herein and full power to agree to all of the matters set forth in this Agreement, in each case
with respect to all of such Equityholder’s Subject Shares. None of such Equityholder’s Subject Shares are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of the Subject Shares, except as
provided hereunder. 
 2.4. Reliance. Such Equityholder has had the opportunity to review the Merger
Agreement and this Agreement with counsel of such Equityholder’s own choosing. Such Equityholder understands and acknowledges that the Company is entering into the Merger Agreement in reliance upon such Equityholder’s execution, delivery
and performance of this Agreement. 
 2.5.    Absence of Litigation. With respect to such
Equityholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of such Equityholder, threatened against, such Equityholder or any of such Equityholder’s properties or assets
(including the shares of Ash Common Stock) that could reasonably be expected to prevent, delay or impair the ability of such Equityholder to perform its obligations hereunder or to consummate the transactions contemplated hereby. 

2.6    No Brokers. Neither such Equityholder nor any of its Representatives or Affiliates has employed or
made any agreement with any broker, finder or similar agent or any Person which will result in the obligation of such Equityholder, the Company, Ash, or any of their respective Affiliates to pay any finder’s fee, brokerage fees or commission or
similar payment in connection with the transactions contemplated hereby. 
 ARTICLE III 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

The Company represents and warrant to each Equityholder that: 

3.1. Organization; Authorization. The Company is a Delaware corporation. The consummation of the transactions
contemplated hereby are within the Company’s corporate powers and have been duly authorized by all necessary corporate actions on the part of the Company. The Company has full power and authority to execute, deliver and perform this Agreement.

  
 3 

 3.2. Binding Agreement. This Agreement has been duly authorized, executed and
delivered by the Company and constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions. 

ARTICLE IV 

MISCELLANEOUS 

4.1. Notices. All notices, requests and other communications to either party hereunder shall be in writing (including
facsimile transmission) and shall be given, (a) if to the Company, in accordance with the provisions of the Merger Agreement and (b) if to any Equityholder, to such Equityholder’s address set forth on a signature page hereto, or to such other
address as such Equityholder may hereafter specify in writing to the Company for such purpose. 
 4.2. Termination. This
Agreement shall terminate automatically and become void and of no further force or effect, without any notice or other action by any Person, upon the earlier of (a) the termination of the Merger Agreement in accordance with its terms and (b) the
Closing. Upon termination of this Agreement, no party shall have any further obligations or liabilities under this Agreement; provided, however, that the provisions of this Article IV shall survive any termination of this Agreement. 

4.3. Amendments and Waivers. Any provision of this Agreement may be amended or waived if such amendment or waiver is in
writing and is signed, in the case of an amendment, by each party to this Agreement or, in the case of a waiver, by the party against whom the waiver is to be effective. No failure or delay by either party in exercising any right, power or privilege
hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. 

4.4. Binding Effect; Benefit; Assignment. The provisions of this Agreement shall be binding upon and shall inure to the
benefit of the parties hereto and their respective successors and permitted assigns. Except as set forth in Section 1.3, no provision of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities hereunder upon
any person other than the parties hereto and their respective successors and assigns. Neither party may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the consent of the other party hereto. 

4.5. Governing Law; Venue. This Agreement shall be governed by and construed in accordance with the laws of
the State of Delaware without regard to its rules of conflict of laws. The Company and each Equityholder hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the Delaware Court of Chancery, or if such court does
not have proper jurisdiction, then the Federal court of the U.S. located in the State of Delaware, and appellate courts therefrom, (collectively, the “Delaware Courts”) for any litigation arising out of or relating to this Agreement
and the transactions contemplated hereby (and agrees not to commence any litigation relating thereto except in such courts), waives any objection to the laying of venue of any such litigation in the Delaware Courts and agrees not to plead or claim
in any Delaware Court that such litigation brought therein has been brought in any inconvenient forum. Each of the parties hereto agrees that service of process may be made on such party by prepaid certified mail with a proof of mailing receipt
validated by the United States Postal Service constituting evidence of valid service. Service made pursuant to the foregoing shall have the same legal force and effect as if served upon such party personally within the State of Delaware. EACH OF THE
PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. 

4.6. Counterparts. The parties may execute this Agreement in one or more counterparts, each of which will be deemed an
original and all of which, when taken together, will be deemed to constitute one and the same agreement. Any signature page hereto delivered by facsimile machine or by e-mail (including in 

  
 4 

 
portable document format (pdf), as a joint photographic experts group (jpg) file, electronic signature, or otherwise) shall be binding to the same extent as an original signature page, with
regard to any agreement subject to the terms hereof or any amendment thereto and may be used in lieu of the original signatures for all purposes. Each party that delivers such a signature page agrees to later deliver an original counterpart to any
other party that requests it. 
 4.7. Entire Agreement. This Agreement constitutes the entire agreement between the
parties with respect to the subject matter of this Agreement and supersedes all prior agreements and understandings, both oral and written, between the parties with respect to its subject matter. 

4.8. Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent
jurisdiction or other Governmental Authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired
or invalidated so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to either party. Upon such a determination, the parties shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible. 

4.9. Specific Performance. The parties hereto agree that the Company would be irreparably damaged if for any reason any
Equityholder fails to perform any of its obligations under this Agreement and that the Company may not have an adequate remedy at law for money damages in such event. Accordingly, the Company shall be entitled to specific performance and injunctive
and other equitable relief to prevent breaches of this Agreement or to enforce specifically the performance of the terms and provisions hereof in any Delaware Court, in addition to any other remedy to which they are entitled at law or in equity, in
each case without posting bond or other security, and without the necessity of proving actual damages. 
 4.10. Headings.
The Section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. 

4.11. No Presumption. This Agreement shall be construed without regard to any presumption or rule requiring construction or
interpretation against the party drafting or causing any instrument to be drafted. 
 4.12. Further Assurances. Each of
the parties hereto will execute and deliver, or cause to be executed and delivered, all further documents and instruments and use their respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all
things necessary under applicable Law to perform their respective obligations as expressly set forth under this Agreement. 

4.13. Interpretation. Unless the context otherwise requires, as used in this Agreement: (a)
“or” is not exclusive; (b) “including” and its variants mean “including, without limitation” and its variants; (c) words defined in the singular have the parallel meaning in the plural and vice versa; (d) words of one
gender shall be construed to apply to each gender; and (e) the terms “Article,” “Section” and “Schedule” refer to the specified Article, Section or Schedule of or to this Agreement. 

4.14. Obligations; Capacity as Equityholder. The obligations of each Equityholder under this Agreement are
several and not joint, and no Equityholder shall have any liability or obligation under this Agreement for any breach hereunder by any other Equityholder. Each Equityholder signs this Agreement solely in such Equityholder’s capacity as a holder
of shares of Ash Common Stock, and not in such Equityholder’s capacity as a director, officer or employee of Ash or in such Equityholder’s capacity as a trustee or fiduciary of any employee benefit plan or trust. Notwithstanding anything
herein to the contrary, nothing herein shall in any way restrict a director or officer of Ash in the exercise of his or her fiduciary duties as a director or officer of Ash or in his or her capacity as a trustee or fiduciary of any employee benefit
plan or trust, or prevent any director or officer of Ash or any trustee or fiduciary of any employee benefit plan or trust from taking any action in his or her capacity as such director, officer, trustee or fiduciary. 

  
 5 

 4.15. Conversion or Exercise. Nothing contained in this
Agreement shall require any Equityholder (or shall entitle any proxy of such Equityholder) to (a) convert, exercise or exchange any option, warrants or convertible securities in order to obtain any underlying Subject Shares or (b) vote, or execute
any consent with respect to, any Subject Shares underlying such options, warrants or convertible securities that have not yet been issued as of the applicable record date for that vote or consent. 

4.16. Representations and Warranties. The representations and warranties contained in this Agreement and in
any certificate or other writing delivered pursuant hereto shall not survive the Closing or the termination of this Agreement. 

4.17. No Agreement Until Executed. Irrespective of negotiations among the parties or the exchanging of drafts
of this Agreement, this Agreement shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and until (a) the Board of Directors of Ash has approved, for purposes of any
applicable anti-takeover laws and regulations, and any applicable provision of Ash’s organizational documents, the possible acquisition of the Company by Ash pursuant to the Merger Agreement and (b) the Merger Agreement is executed by all
parties thereto. 
 (SIGNATURE PAGES FOLLOW) 

  
 6 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the
date first written above. 
  

					
	ONCOGENEX PHARMACEUTICALS, INC.
		
	By:	 	  

		 	Name:  	 	  

		 	Title:	 	  

  
 [Signature Page
to Support Agreement] 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the
date first written above. 
  

					
	 [ENTITY OR INDIVIDUAL EQUITYHOLDER ]

		
	By:	 	  

		 	Name:  	 	  

		 	Title:	 	  

  
 [Signature Page
to Support Agreement] 

 Schedule A 

 

					
	 Name of Equityholder
	  	No. of Shares of Ash Common Stock	 
	 Richard Stewart
	  	 	5,300	  
	 Anthony Clarke
	  	 	1,500	  
	 Susan Clarke
	  	 	1,000	  
	 Timothy Clarke
	  	 	1,500	  
	 Robert Schacter
	  	 	4,500	  
	 Ronald Martell
	  	 	2,100	  
	 Caroline Loewy
	  	 	630EX-10.2

 Exhibit 10.2 

SUPPORT AGREEMENT 
 This
SUPPORT AGREEMENT (this “Agreement”), dated as of January 5, 2017, is by and among Achieve Life Science, Inc., a Delaware corporation (the “Company”, or “Ash”), and the equityholders of
OncoGenex Pharmaceuticals, Inc., a Delaware corporation (“Arrow”), set forth on Schedule A hereto (each, an “Equityholder” and collectively, the “Equityholders”). 

WHEREAS, as of the date hereof, each Equityholder is the holder of the number of shares of common stock, par value $0.001 per share, of
Arrow (“Arrow Common Stock”) and/or options to purchase shares of Arrow Common Stock (“Options”) set forth opposite such Equityholder’s name on Schedule A (all such shares of Arrow Common Stock set forth
on Schedule A, together with any shares of Arrow Common Stock that are issued upon exercise of Options or otherwise hereafter issued to or otherwise acquired or owned by such Equityholder prior to the termination of this Agreement being
referred to herein as the “Subject Shares”);
 WHEREAS, Arrow, Ash Acquisition Sub, Inc., Ash Acquisition Sub 2,
Inc. and the Company propose to enter into that certain Merger Agreement, dated as of the date hereof (the “Merger Agreement”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to
such terms in the Merger Agreement; and 
 WHEREAS, as a condition to the Company’s willingness to enter into the Merger
Agreement and as an inducement and in consideration therefor, each Equityholder (in such Equityholder’s capacity as a holder of shares of Arrow Common Stock and/or Options) has agreed to, enter into this Agreement. 

NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth
below and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows: 

ARTICLE I 
 VOTING
AGREEMENT; GRANT OF PROXY 
 Each Equityholder hereby covenants and agrees that: 

1.1. Voting of Subject Shares. Subject to the remaining terms of this Section 1.1, at every meeting of the
holders of Arrow Common Stock (the “Arrow Stockholders”), however called, and at every adjournment or postponement thereof (or pursuant to a written consent if the Arrow Stockholders act by written consent in lieu of a meeting),
such Equityholder shall, or shall cause the holder of record on any applicable record date to, be present (in person or by proxy) and to vote such Equityholder’s Subject Shares (a) in favor of the approval of (i) the Merger Agreement, (ii) the
issuance of Arrow Common Stock in the First Merger, (iii) the Arrow Reverse Stock Split, (iv) any proposal to adjourn or postpone any meeting to a later date, if there are not sufficient votes for the approval of any of the foregoing matters on the
date on which such meeting is held, and (v) any other proposal included in the Proxy Statement/Prospectus in connection with, or related to, the consummation of the Mergers that the Board of Directors of Arrow (the “Arrow Board”)
has recommended that the Arrow Stockholders vote in favor of; and (b) against any Acquisition Proposal with respect to Arrow.

1.2. No Inconsistent Arrangements. Except as expressly permitted hereunder or under the Merger Agreement, such Equityholder
shall not, directly or indirectly, (a) create any Encumbrance other than restrictions imposed by applicable Law or pursuant to this Agreement on any shares of Arrow Common Stock or Options, (b) transfer, sell, assign, encumber, pledge, grant, gift
or otherwise dispose of (collectively, “Transfer”), or enter into any contract with respect to any Transfer of the shares of Arrow Common Stock or Options or any interest therein or publicly announce its intention to Transfer any of
its shares of Arrow Common Stock or Options, (c) grant or permit the grant of any proxy, power of attorney or other authorization in or with 

 
respect to the shares of Arrow Common Stock or Options, (d) deposit or permit the deposit of the Subject Shares into a voting trust or enter into a voting agreement or arrangement with respect to
the Subject Shares or (e) take any action that would make any representation or warranty of such Equityholder herein untrue or incorrect in any material respect, or have the effect of preventing such Equityholder from performing such
Equityholder’s obligations hereunder. Notwithstanding the foregoing, subject to any restrictions on transfer applicable to such shares of Arrow Common Stock or Options provided pursuant to the terms of the Option and any stock option plan under
which such Option was granted, (x) such Equityholder may make Transfers of the shares of Arrow Common Stock or Options by will, operation of law, or for estate planning purposes, provided, the shares of Arrow Common Stock or Options, as
applicable, shall continue to be bound by this Agreement and each transferee of such shares of Arrow Common Stock or Options shall agree in writing to be bound by the terms and conditions of this Agreement and either such Equityholder or the
transferee shall provide the Company with a copy of such agreement promptly upon consummation of any such Transfer and (y) such Equityholder shall take all actions reasonably necessary to consummate the transactions contemplated by the Merger
Agreement. 
 1.3. Documentation and Information. Such Equityholder shall permit and hereby authorizes the Company and
Arrow to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that the Company or Arrow reasonably determines to be necessary in connection with the transactions contemplated by
the Merger Agreement, such Equityholder’s identity and ownership of the shares of Arrow Common Stock and/or Options and the nature of such Equityholder’s commitments and obligations under this Agreement. Each of Arrow and Ash is an
intended third-party beneficiary of this Section 1.3. 
 1.4. Irrevocable Proxy. Each Equityholder
hereby revokes (or agrees to cause to be revoked) any proxies that such Equityholder has heretofore granted with respect to the Subject Shares. Such Equityholder hereby irrevocably appoints the Company, and any individual designated in writing by
it, as attorney-in-fact and proxy for and on behalf of such Equityholder, for and in the name, place and stead of such Equityholder, to: (a) attend any and all meetings of the Arrow Equityholders, (b) vote, express consent or dissent or issue
instructions to the record holder to vote such Equityholder’s Subject Shares in accordance with the provisions of Section 1.1 at any and all meetings of the Arrow Equityholders or in connection with any action sought to be taken by written
consent of the Arrow Equityholders without a meeting and (c) grant or withhold, or issue instructions to the record holder to grant or withhold, consistent with the provisions of Section 1.1, all written consents with respect to the Subject Shares
at any and all meetings of the Equityholders or in connection with any action sought to be taken by written consent without a meeting. The Company agrees not to exercise the proxy granted herein for any purpose other than the purposes expressly
described in this Agreement. The foregoing proxy shall be deemed to be a proxy coupled with an interest, is irrevocable (and as such shall survive and not be affected by the death, incapacity, mental illness or insanity of such Equityholder, as
applicable) until the termination of the Merger Agreement and shall not be terminated by operation of law or upon the occurrence of any other event other than the termination of this Agreement pursuant to Section 4.2. Such Equityholder
authorizes such attorney and proxy to substitute any other Person to act hereunder, to revoke any substitution and to file this proxy and any substitution or revocation with the Secretary of Arrow. Such Equityholder hereby affirms that the proxy set
forth in this Section 1.4 is given in connection with and granted in consideration of and as an inducement to the Company to enter into the Merger Agreement and that such proxy is given to secure the obligations of such Equityholder under Section
1.1. The proxy set forth in this Section 1.4 is executed and intended to be irrevocable, subject, however, to its automatic termination upon the termination of this Agreement pursuant to Section 4.2. 

1.5. No Solicitation of Merger. Without limiting and subject to the provisions of Section 4.14 hereof, such
Equityholder shall not, directly or indirectly, knowingly take any action that Arrow is not permitted to take pursuant to Section 4 of the Merger Agreement. 

  
 2 

 ARTICLE II 

REPRESENTATIONS AND WARRANTIES OF THE EQUITYHOLDERS 

Each Equityholder, severally but not jointly as to any other Equityholder, represents and warrants to the Company that: 

2.1. Authorization; Binding Agreement. Such Equityholder has full legal capacity, right and authority to
execute and deliver this Agreement and to perform such Equityholder’s obligations hereunder and to consummate the transactions contemplated hereby. Such Equityholder has full power and authority to execute, deliver and perform this Agreement.
This Agreement has been duly and validly executed and delivered by such Equityholder, and constitutes a valid and binding obligation of such Equityholder enforceable against such Equityholder in accordance with its terms, subject to the
Enforceability Exceptions. The execution and delivery by the Equityholder of this Agreement does not (a) conflict with or violate any law applicable to the Equityholder or by which any property or asset of the Equityholder is bound; or (b) result in
any breach or default under any Contract to which the Equityholder is a party or to which any of the Equityholder’s property or assets are subject, except, in each case, as would not reasonably be expected to adversely affect the ability of the
Equityholder to consummate the transactions contemplated by this Agreement, the Merger Agreement or the ancillary agreements to which the Equityholder is to be a party pursuant to the Merger Agreement. 

2.2. Ownership of Arrow Common Stock and Options; Total Shares. Such Equityholder is the sole record or beneficial owner
(as defined in Rule 13d-3 under the Exchange Act) of such Equityholder’s shares of Arrow Common Stock and Options listed on Schedule A opposite such Equityholder’s name and has good and marketable title to such shares of Arrow
Common Stock and Options free and clear of any Encumbrance (including, with respect to shares of Arrow Common Stock, any restriction on the right to vote or otherwise transfer the shares of Arrow Common Stock), except as (a) provided hereunder, (b)
pursuant to any applicable restrictions on transfer under the Securities Act, (c) subject to any risk of forfeiture with respect to any shares of Arrow Common Stock granted to such Equityholder under an employee benefit plan of Arrow and (d) with
respect to Options, provided pursuant to the terms of the Option and any stock option plan under which such Option was granted. The shares of Arrow Common Stock and Options listed on Schedule A opposite such Equityholder’s name
constitute all of the shares of Arrow Common Stock and/or Options owned by such Equityholder as of the date hereof. Except pursuant to this Agreement, no Person has any contractual or other right or obligation to purchase or otherwise acquire any of
such Equityholder’s shares of Arrow Common Stock and Options.
 2.3. Voting Power. Except as set forth
on Schedule A, such Equityholder has full voting power, with respect to such Equityholder’s Subject Shares, and full power of disposition, full power to issue instructions with respect to the matters set forth herein and full power to
agree to all of the matters set forth in this Agreement, in each case with respect to all of such Equityholder’s Subject Shares. None of such Equityholder’s Subject Shares are subject to any proxy, voting trust or other agreement or
arrangement with respect to the voting of the Subject Shares, except as provided hereunder. 
 2.4. Reliance.
Such Equityholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of such Equityholder’s own choosing. Such Equityholder understands and acknowledges that the Company is entering into the Merger
Agreement in reliance upon such Equityholder’s execution, delivery and performance of this Agreement. 
 2.5. Absence of
Litigation. With respect to such Equityholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of such Equityholder, threatened against, such Equityholder or
any of such Equityholder’s properties or assets (including the shares of Arrow Common Stock and Options) that could reasonably be expected to prevent, delay or impair the ability of such Equityholder to perform its obligations hereunder or to
consummate the transactions contemplated hereby. 

  
 3 

 2.6 No Brokers. Neither such Equityholder nor any of its Representatives or
Affiliates has employed or made any agreement with any broker, finder or similar agent or any Person which will result in the obligation of such Equityholder, the Company, Arrow, or any of their respective Affiliates to pay any finder’s fee,
brokerage fees or commission or similar payment in connection with the transactions contemplated hereby. 
 ARTICLE III 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

The Company represents and warrant to each Equityholder that: 

3.1. Organization; Authorization. The Company is a Delaware corporation. The consummation of the transactions
contemplated hereby are within the Company’s corporate powers and have been duly authorized by all necessary corporate actions on the part of the Company. The Company has full power and authority to execute, deliver and perform this Agreement.

 3.2. Binding Agreement. This Agreement has been duly authorized, executed and delivered by the Company and constitutes
a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions. 

ARTICLE IV 

MISCELLANEOUS 

4.1. Notices. All notices, requests and other communications to either party hereunder shall be in writing (including
facsimile transmission) and shall be given, (a) if to the Company, in accordance with the provisions of the Merger Agreement and (b) if to any Equityholder, to such Equityholder’s address set forth on a signature page hereto, or to such other
address as such Equityholder may hereafter specify in writing to the Company for such purpose. 
 4.2. Termination. This
Agreement shall terminate automatically and become void and of no further force or effect, without any notice or other action by any Person, upon the earlier of (a) the termination of the Merger Agreement in accordance with its terms and (b) the
Closing. Upon termination of this Agreement, no party shall have any further obligations or liabilities under this Agreement; provided, however, that the provisions of this Article IV shall survive any termination of this Agreement. 

4.3. Amendments and Waivers. Any provision of this Agreement may be amended or waived if such amendment or waiver is in
writing and is signed, in the case of an amendment, by each party to this Agreement or, in the case of a waiver, by the party against whom the waiver is to be effective. No failure or delay by either party in exercising any right, power or privilege
hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. 

4.4. Binding Effect; Benefit; Assignment. The provisions of this Agreement shall be binding upon and shall inure to the
benefit of the parties hereto and their respective successors and permitted assigns. Except as set forth in Section 1.3, no provision of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities hereunder upon
any person other than the parties hereto and their respective successors and assigns. Neither party may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the consent of the other party hereto. 

4.5. Governing Law; Venue. This Agreement shall be governed by and construed in accordance with the laws of
the State of Delaware without regard to its rules of conflict of laws. The Company and each Equityholder hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the Delaware Court of Chancery, or if such court does
not have proper jurisdiction, then the Federal court of the 

  
 4 

 
U.S. located in the State of Delaware, and appellate courts therefrom, (collectively, the “Delaware Courts”) for any litigation arising out of or relating to this Agreement and
the transactions contemplated hereby (and agrees not to commence any litigation relating thereto except in such courts), waives any objection to the laying of venue of any such litigation in the Delaware Courts and agrees not to plead or claim in
any Delaware Court that such litigation brought therein has been brought in any inconvenient forum. Each of the parties hereto agrees that service of process may be made on such party by prepaid certified mail with a proof of mailing receipt
validated by the United States Postal Service constituting evidence of valid service. Service made pursuant to the foregoing shall have the same legal force and effect as if served upon such party personally within the State of Delaware. EACH OF THE
PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. 

4.6. Counterparts. The parties may execute this Agreement in one or more counterparts, each of which will be deemed an
original and all of which, when taken together, will be deemed to constitute one and the same agreement. Any signature page hereto delivered by facsimile machine or by e-mail (including in portable document format (pdf), as a joint photographic
experts group (jpg) file, electronic signature, or otherwise) shall be binding to the same extent as an original signature page, with regard to any agreement subject to the terms hereof or any amendment thereto and may be used in lieu of the
original signatures for all purposes. Each party that delivers such a signature page agrees to later deliver an original counterpart to any other party that requests it. 

4.7. Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject
matter of this Agreement and supersedes all prior agreements and understandings, both oral and written, between the parties with respect to its subject matter. 

4.8. Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent
jurisdiction or other Governmental Authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired
or invalidated so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to either party. Upon such a determination, the parties shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible. 

4.9. Specific Performance. The parties hereto agree that the Company would be irreparably damaged if for any reason any
Equityholder fails to perform any of its obligations under this Agreement and that the Company may not have an adequate remedy at law for money damages in such event. Accordingly, the Company shall be entitled to specific performance and injunctive
and other equitable relief to prevent breaches of this Agreement or to enforce specifically the performance of the terms and provisions hereof in any Delaware Court, in addition to any other remedy to which they are entitled at law or in equity, in
each case without posting bond or other security, and without the necessity of proving actual damages. 
 4.10. Headings.
The Section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. 

4.11. No Presumption. This Agreement shall be construed without regard to any presumption or rule requiring construction or
interpretation against the party drafting or causing any instrument to be drafted. 
 4.12. Further Assurances. Each of
the parties hereto will execute and deliver, or cause to be executed and delivered, all further documents and instruments and use their respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all
things necessary under applicable Law to perform their respective obligations as expressly set forth under this Agreement. 

  
 5 

 4.13. Interpretation. Unless the context otherwise requires, as
used in this Agreement: (a) “or” is not exclusive; (b) “including” and its variants mean “including, without limitation” and its variants; (c) words defined in the singular have the parallel meaning in the plural
and vice versa; (d) words of one gender shall be construed to apply to each gender; and (e) the terms “Article,” “Section” and “Schedule” refer to the specified Article, Section or Schedule of or to this Agreement. 

4.14. Obligations; Capacity as Equityholder. The obligations of each Equityholder under this Agreement are
several and not joint, and no Equityholder shall have any liability or obligation under this Agreement for any breach hereunder by any other Equityholder. Each Equityholder signs this Agreement solely in such Equityholder’s capacity as a holder
of shares of Arrow Common Stock and/or a holder of Options, and not in such Equityholder’s capacity as a director, officer or employee of Arrow or in such Equityholder’s capacity as a trustee or fiduciary of any employee benefit plan or
trust. Notwithstanding anything herein to the contrary, nothing herein shall in any way restrict a director or officer of Arrow in the exercise of his or her fiduciary duties as a director or officer of Arrow or in his or her capacity as a trustee
or fiduciary of any employee benefit plan or trust, or prevent any director or officer of Arrow or any trustee or fiduciary of any employee benefit plan or trust from taking any action in his or her capacity as such director, officer, trustee or
fiduciary. 
 4.15. Conversion or Exercise. Nothing contained in this Agreement shall require any
Equityholder (or shall entitle any proxy of such Equityholder) to (a) convert, exercise or exchange any Option, warrants or convertible securities in order to obtain any underlying Subject Shares or (b) vote, or execute any consent with respect to,
any Subject Shares underlying such Options, warrants or convertible securities that have not yet been issued as of the applicable record date for that vote or consent. 

4.16. Representations and Warranties. The representations and warranties contained in this Agreement and in
any certificate or other writing delivered pursuant hereto shall not survive the Closing or the termination of this Agreement. 

4.17. No Agreement Until Executed. Irrespective of negotiations among the parties or the exchanging of drafts
of this Agreement, this Agreement shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and until (a) the Arrow Board has approved, for purposes of any applicable
anti-takeover laws and regulations, and any applicable provision of Arrow’s organizational documents, the possible acquisition of the Company by Arrow pursuant to the Merger Agreement and (b) the Merger Agreement is executed by all parties
thereto. 
 (SIGNATURE PAGES FOLLOW) 

  
 6 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the
date first written above. 
  

					
	ACHIEVE LIFE SCIENCE, INC.
		
	By:	 	  

		 	Name:  	 	  

		 	Title:	 	  

  
 [Signature Page
to Support Agreement] 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the
date first written above. 
  

					
	 [ENTITY OR INDIVIDUAL EQUITYHOLDER ]

		
	By:	 	  

		 	Name:  	 	  

		 	Title:	 	  

  
 [Signature Page
to Support Agreement] 

 Schedule A 

 

					
	 Name of Equityholder
	  	No. of Shares of Arrow Common Stock	 
	 Scott Cormack
	  	 	129,428	  
	 Jack Goldstein
	  	 	17,500	  
	 David Smith
	  	 	9,500	  
	 Neil Clendennin
	  	 	22,421	  
	 Martin Mattingly
	  	 	10,500	  
	 John Bencich
	  	 	9,484	  
	 Cindy Jacobs
	  	 	77,416	  
	 Michelle Griffin
	  	 	73,743	  
	 Stewart Parker
	  	 	12,500	  

  

					
	 Name of Equityholder
	  	Options to Purchase Arrow Common Stock	 
	 Scott Cormack
	  	 	565,000	  
	 Jack Goldstein
	  	 	59,461	  
	 David Smith
	  	 	50,500	  
	 Neil Clendennin
	  	 	48,500	  
	 Martin Mattingly
	  	 	50,500	  
	 John Bencich
	  	 	177,500	  
	 Cindy Jacobs
	  	 	264,500	  
	 Michelle Griffin
	  	 	271,000	  
	 Stewart Parker
	  	 	50,461

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}]]